HDAC inhibitors could shift the balance away from undifferentiated tumor states toward more mature neuronal phenotypes by targeting the acetylation status of histones and hence altering gene expression profiles, which is good for patient prognosis. The gene discussed is HDAC9; the disease is neoplasm.